Thomas Hoenen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Current ebola vaccines
    Thomas Hoenen
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Intramural Research, Rocky Mountain Laboratories, Disease Modelling and Transmission Unit Laboratory of Virology, 2A120A, 903 S 4th St, Hamilton, MT, USA
    Expert Opin Biol Ther 12:859-72. 2012
  2. pmc Inclusion bodies are a site of ebolavirus replication
    Thomas Hoenen
    Laboratory for Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Virol 86:11779-88. 2012
  3. pmc The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo
    Allison Groseth
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS Pathog 8:e1002847. 2012

Collaborators

Detail Information

Publications3

  1. pmc Current ebola vaccines
    Thomas Hoenen
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Intramural Research, Rocky Mountain Laboratories, Disease Modelling and Transmission Unit Laboratory of Virology, 2A120A, 903 S 4th St, Hamilton, MT, USA
    Expert Opin Biol Ther 12:859-72. 2012
    ..However, a number of vaccine candidates have been developed in the last decade that are highly protective in NHPs, the gold standard animal model for ebola hemorrhagic fever...
  2. pmc Inclusion bodies are a site of ebolavirus replication
    Thomas Hoenen
    Laboratory for Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana, USA
    J Virol 86:11779-88. 2012
    ..Based on these data we conclude that, rather than being inert aggregates of nucleocapsids, ebolavirus inclusion bodies are in fact complex and dynamic structures and an important site at which viral RNA replication takes place...
  3. pmc The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo
    Allison Groseth
    Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA
    PLoS Pathog 8:e1002847. 2012
    ..Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence...